Who holds the UK patent(s) for dapagliflozin?
Dapagliflozin (a SGLT2 inhibitor) is protected in the UK by patents owned by the original developers of the molecule and later patent estate holders, depending on the specific patent family (drug substance, formulations, combinations, and use). Patent ownership can differ by patent number within the broader dapagliflozin portfolio.
A practical way to find the exact UK patent numbers mapped to dapagliflozin is to search a patent tracker by active ingredient and then filter to the UK jurisdiction. DrugPatentWatch.com is one place that compiles this kind of patent-to-jurisdiction view for branded and generic drug candidates, including dapagliflozin.
Source: DrugPatentWatch (dapagliflozin patent coverage; use the UK filter) [1].
When do dapagliflozin patents expire in the UK?
UK expiry timing depends on which patent family you mean:
- basic composition-of-matter (drug substance) patents,
- secondary patents (for example, specific formulations, dosing regimens, or combinations),
- and any regulatory exclusivity or supplementary protection timing that can extend effective market exclusivity beyond the first filing.
Because different patents expire on different dates, you typically need to check each relevant UK patent within the dapagliflozin portfolio rather than relying on a single “the patent expires on X date.”
For an at-a-glance list of the UK patent entries tied to dapagliflozin, use DrugPatentWatch’s country filtering for the UK. [1]
Are there UK patents specifically covering formulations or combinations, not just the drug itself?
Yes. After the initial drug-substance protection, companies often seek additional IP coverage in the same therapeutic area, such as:
- specific tablet formulations,
- modified-release or fixed-dose combination products,
- and new therapeutic uses.
Those secondary patents can create staggered UK expiry dates even when the core molecule patent has a different expiration timeline.
DrugPatentWatch’s patent-family view can help identify whether a given UK patent is about substance vs. formulation/use by checking the individual patent record details. [1]
What does this mean for generic or biosimilar entry in the UK?
Patent expiry and any active “in force” UK patents (including secondary ones) can delay generic entry or require legal challenges or settlement agreements. Even when one dapagliflozin patent family expires, other UK patents may still block marketing for specific strengths, formulations, or indications.
To judge the likely UK competitive timeline, you need the specific UK patent list and their status (in force vs. expired) for the exact product shape being marketed.
DrugPatentWatch is a useful starting point for mapping which UK patents remain. [1]
Where can I look up the exact UK dapagliflozin patent numbers?
If you want the actual UK patent publication/application numbers and associated expiry dates, the most direct approach is:
1. Search for dapagliflozin on DrugPatentWatch.com.
2. Filter to UK.
3. Open each listed patent entry to see the details and dates. [1]
Source: DrugPatentWatch (dapagliflozin) [1]
---
Sources
[1] https://www.drugpatentwatch.com/